Imatinib Quantification in rat plasma by high performance liquid chromatography with ultra violet detection - An application to Preclinical Pharmacokinetic study.
暂无分享,去创建一个
Vivek Kumar | P. Musmade | K. Bhat | C. Mohan | Ranjitha S. Shetty | A. Theerthahalli | S. Kini | J. Patel
[1] J. Biollaz,et al. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. , 2008, Journal of mass spectrometry : JMS.
[2] F. Lee,et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor , 2008, Cancer Chemotherapy and Pharmacology.
[3] J. Schellens,et al. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. , 2007, Biomedical chromatography : BMC.
[4] Gunther Guetens,et al. Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. , 2006, Journal of separation science.
[5] P. Berthaud,et al. Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry , 2005, Therapeutic drug monitoring.
[6] J. J. Berzas Nevado,et al. Nonaqueous capillary electrophoresis method for the analysis of gleevec and its main metabolite in human urine. , 2005, Journal of chromatography. A.
[7] Stephen K Burley,et al. A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[8] M. Ogura,et al. Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study , 2004, International journal of hematology.
[9] J. Fletcher,et al. Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Gupta,et al. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[11] T. Buclin,et al. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[12] F. Balis,et al. Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates , 2004, Clinical Cancer Research.
[13] M. Highley,et al. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. A.
[14] G. Castañeda,et al. Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[15] M. Egorin,et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[16] F. Tse,et al. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. , 2002, Journal of pharmaceutical and biomedical analysis.
[17] B. Druker,et al. STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.
[18] F. Tse,et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[19] S. Primack,et al. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. , 2004, Haematologica.
[20] M. Hearn. [9] Reversed-phase high-performance liquid chromatography , 1984 .